Syringolin A Selectively Labels the 20 S Proteasome in Murine EL4 and Wild-Type and Bortezomib-Adapted Leukaemic Cell Lines

Chemical Genomics Centre der Max-Planck-Gesellschaft, Otto-Hahn-Strasse 15, 44227 Dortmund, Germany.
ChemBioChem (Impact Factor: 3.09). 11/2009; 10(16):2638-43. DOI: 10.1002/cbic.200900411
Source: PubMed


The natural product syringolin A (SylA) is a potent proteasome inhibitor with promising anticancer activities. To further investigate its potential as a lead structure, selectivity profiling with cell lysates was performed. At therapeutic concentrations, a rhodamine-tagged SylA derivative selectively bound to the 20 S proteasome active sites without detectable off-target labelling. Additional profiling with lysates of wild-type and bortezomib-adapted leukaemic cell lines demonstrated the retention of this proteasome target and subsite selectivity as well as potency even in clinically relevant cell lines. Our studies, therefore, propose that further development of SylA might indeed result in an improved small molecule for the treatment of leukaemia.

Download full-text


Available from: Bogdan Iulius Florea,
  • Source
    • "with an N-terminally dimethylated isoleucine residue. The Michael system in the (4S)-amino-(2E)-pentenoic acid unit is, thus, potentially bioreactive (Drahl et al., 2005); in fact, covalently binding cysteine protease inhibitors, proteasome as well as GAPDH inhibitors, with such Michael acceptor units have been reported (Clerc et al., 2009a, 2009b; Groll et al., 2008; Kaschani et al., 2012; Powers et al., 2002). In Sym4, this chemical moiety is uniquely linked to a highly rigid mmp group, which could influence the bioreactivity and/or target specificity of this natural product. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The marine natural product symplostatin 4 (Sym4) has been recognized as a potent antimalarial agent. However, its mode of action and, in particular, direct targets have to date remained elusive. We report a chemical synthesis of Sym4 and show that Sym4-treatment of P. falciparum-infected red blood cells (RBCs) results in the generation of a swollen food vacuole phenotype and a reduction of parasitemia at nanomolar concentrations. We furthermore demonstrate that Sym4 is a nanomolar inhibitor of the P. falciparum falcipains in infected RBCs, suggesting inhibition of the hemoglobin degradation pathway as Sym4's mode of action. Finally, we reveal a critical influence of the unusual methyl-methoxypyrrolinone (mmp) group of Sym4 for potent inhibition, indicating that Sym4 derivatives with such a mmp moiety might represent viable lead structures for the development of antimalarial falcipain inhibitors.
    Chemistry & biology 12/2012; 19(12):1546-55. DOI:10.1016/j.chembiol.2012.09.020 · 6.65 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Syringolins are a class of cyclic tripeptide natural products that are potent and irreversible inhibitors of the eukaryotic proteasome. In addition to being hybrid NRPS/PKS molecules, they also feature an unusual ureido-linkage (red) between two amino acid monomers. Here we report the first in vitro characterization of enzymatic ureido-linkage formation which is catalyzed by an NRPS, SylC. Using (13)C- and (18)O-labeling studies, we show that biosynthesis occurs via N-carboxylation to form an initial N-carboxy-aminoacyl-S-Ppant enzyme intermediate which undergoes intramolecular cyclization followed by condensation with a second amino acid to form the ureido-containing dipeptide product.
    Journal of the American Chemical Society 12/2009; 131(51):18263-5. DOI:10.1021/ja909170u · 12.11 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The ubiquitin-proteasome system plays a critical role in selective protein degradation and regulates almost all cellular events such as cell cycle progression, signal transduction, cell death, immune responses, metabolism, protein quality control, development, and neuronal function. The recent approval of bortezomib, a synthetic proteasome inhibitor, for the treatment of relapsed multiple myeloma has opened the way to the discovery of drugs targeting the proteasome and ubiquitinating and deubiquitinating enzymes as well as the delivery system. To date, various synthetic and natural products have been reported to inhibit the components of the ubiquitin-proteasome system. Here, we review natural products targeting the ubiquitin-proteasome system as well as synthetic compounds with potent inhibitory effects.
    Planta Medica 02/2010; 76(11):1064-74. DOI:10.1055/s-0029-1240901 · 2.15 Impact Factor
Show more